Elranatamab Access for Multiple Myeloma
(MagnetisMM15 Trial)
Trial Summary
What is the purpose of this trial?
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the drug Elranatamab for treating multiple myeloma?
Elranatamab has shown promising results in clinical trials for treating relapsed or refractory multiple myeloma, with significant response rates and long-term tolerability. In the MagnetisMM-1 trial, 63.6% of patients responded to the treatment, and in the MagnetisMM-3 trial, 61.0% of patients achieved a confirmed response, indicating its effectiveness in managing this condition.12345
How is the drug Elranatamab unique in treating multiple myeloma?
Elranatamab is unique because it is a bispecific antibody that targets both BCMA on myeloma cells and CD3 on T cells, activating the T cells to attack the cancer cells. It is administered subcutaneously and has shown promising results in patients who have already undergone multiple other treatments, offering a new option for those with relapsed or refractory multiple myeloma.13456
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
This trial is for people with Multiple Myeloma who are benefiting from Elranatamab in ongoing Pfizer studies. They must agree to follow reproductive safety measures and cannot join if they've left the original study or have conditions that increase risk or suicidal thoughts recently.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive elranatamab monotherapy until disease progression, unacceptable toxicity, withdrawal of consent, study termination, or commercial availability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Elranatamab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University